As of 2024-12-14, the Relative Valuation of Taysha Gene Therapies Inc (TSHA) is (2.02) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.25 USD, the upside of Taysha Gene Therapies Inc based on Relative Valuation is -189.6%.
The range of the Relative Valuation is (1.26) - (2.12) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.5x - 24.4x | 17.5x |
| Forward P/E multiples | 11.3x - 19.1x | 18.8x |
| Fair Price | (1.26) - (2.12) | (2.02) |
| Upside | -155.9% - -194.4% | -189.6% |
| Date | P/E |
| 2024-11-22 | -22.23 |
| 2024-11-21 | -19.62 |
| 2024-11-20 | -18.09 |
| 2024-11-19 | -19.08 |
| 2024-11-18 | -20.52 |
| 2024-11-15 | -18.54 |
| 2024-11-14 | -20.43 |
| 2024-11-13 | -19.89 |
| 2024-11-12 | -21.51 |
| 2024-11-11 | -14.67 |
| 2024-11-08 | -13.50 |
| 2024-11-07 | -12.78 |
| 2024-11-06 | -12.33 |
| 2024-11-05 | -11.43 |
| 2024-11-04 | -12.06 |
| 2024-11-01 | -13.77 |
| 2024-10-31 | -15.21 |
| 2024-10-30 | -16.83 |
| 2024-10-29 | -16.92 |
| 2024-10-28 | -17.73 |
| 2024-10-25 | -17.91 |
| 2024-10-24 | -17.73 |
| 2024-10-23 | -17.73 |
| 2024-10-22 | -17.91 |
| 2024-10-21 | -18.18 |
| 2024-10-18 | -18.54 |
| 2024-10-17 | -18.27 |
| 2024-10-16 | -18.27 |
| 2024-10-15 | -17.55 |
| 2024-10-14 | -17.91 |
| 2024-10-11 | -18.09 |
| 2024-10-10 | -17.82 |
| 2024-10-09 | -18.00 |
| 2024-10-08 | -18.09 |
| 2024-10-07 | -17.82 |
| 2024-10-04 | -18.09 |
| 2024-10-03 | -18.18 |
| 2024-10-02 | -18.45 |
| 2024-10-01 | -18.18 |
| 2024-09-30 | -18.09 |
| 2024-09-27 | -18.63 |
| 2024-09-26 | -18.90 |
| 2024-09-25 | -18.09 |
| 2024-09-24 | -18.54 |
| 2024-09-23 | -18.27 |
| 2024-09-20 | -19.35 |
| 2024-09-19 | -19.71 |
| 2024-09-18 | -19.35 |
| 2024-09-17 | -19.62 |
| 2024-09-16 | -19.53 |